Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Burch Urethropexy and Mid-urethral Sling Performed Concomitantly With a Sacral Colpopexy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00934999
Recruitment Status : Completed
First Posted : July 8, 2009
Last Update Posted : March 22, 2016
Sponsor:
Collaborators:
Spectrum Health Hospitals
Saint Luke's Health System
Information provided by (Responsible Party):
Emanuel Trabuco, Mayo Clinic

Brief Summary:

I. Specific Aims

Pelvic organ prolapse is a common and distressing condition that is frequently associated with stress urinary incontinence (SUI) and often requires surgical repair. Abdominal sacral colpopexy is the preferred operation for repairing pelvic prolapse. As many as 91% of women with pelvic organ prolapse undergoing sacral colpopexy also experience SUI. In addition, up to 44% of previously continent women develop SUI incontinence after sacral colpopexy: perhaps because a sacral colpopexy may predispose to opening of the bladder neck if secured too tightly. The selection of a surgical procedure to prevent and manage SUI in women undergoing sacral colpopexy is empiric rather than evidence-based. Conceptually, a mid-urethral sling may be more effective than a Burch procedure for preventing urinary leakage because a sling provides outlet resistance beyond the bladder neck and therefore it may compensate for a downward tension on the bladder neck resulting from the sacral colpopexy. Indeed, clinical observations suggest that a mid-urethral sling is effective among women who have persistent urinary incontinence after sacral colpopexy with a Burch procedure. Therefore, the investigators' global hypothesis is that a mid-urethral sling is preferable to a Burch procedure for preventing and improving stress urinary incontinence in women undergoing sacral colpopexy for pelvic organ prolapse. The investigators' SPECIFIC AIMS are to evaluate objective and subjective outcomes at 6, 12 and 24 months in 124 women with urinary incontinence and advanced pelvic organ prolapse. All women will be undergoing a sacral colpopexy and will be randomized to either a Burch procedure or a mid-urethral sling. The primary endpoint is composite continence at 6 months while secondary endpoints will include composite continence and subjective measures of incontinence, patient satisfaction and morbidity associated with these procedures. The investigators' hypotheses are as follows:

  1. At 6 months, urinary continence rates will be higher after a mid-urethral than after a Burch procedure. Urine continence will be assessed by composite measure of incontinence: no subjective complaint, no interim treatment, and negative standardized stress test performed by a masked observer. This assessment will be repeated at 12 and 24 months post-operatively to establish the medium term continence of the two procedures. Subjective continence and patient satisfaction measures will be obtained at each of the above visits using standardized questionnaires and pelvic organ support will be quantified by Pelvic Organ Prolapse-Quantification (POP-Q) scores.
  2. Early events (e.g., blood loss, operative time, intra-operative complications (vascular, bowel and urological injuries), in-hospital complications (need for transfusion, febrile morbidity, thrombotic events, wound infection, length of stay, duration of bladder catheterization and ileus) and delayed postoperative complications (e.g., wound infection, mesh erosion, bowel obstruction and obstructed voiding) will be collected to compare the safety of each procedure.

Condition or disease Intervention/treatment Phase
Urinary Incontinence Procedure: Burch urethropexy Procedure: Synthetic mid-urethral sling (TVT) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 113 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Randomized Comparison of Concomitant Incontinence Procedures Performed With Abdominal Sacral Colpopexy: the Burch Versus Mid-urethral Sling Trial
Study Start Date : June 2009
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Burch
Patients will receive a Burch urethropexy at the time of an abdominal sacral colpopexy.
Procedure: Burch urethropexy
Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).

Experimental: Mid-urethral sling
Patients will receive a mid-urethral sling at the time of an abdominal sacral colpopexy.
Procedure: Synthetic mid-urethral sling (TVT)
Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
Other Name: TVT




Primary Outcome Measures :
  1. The primary endpoint is to compare the proportion of patients who are continent in each group. Continence requires negative standardized stress test performed by a masked observer; no interim re-treatment for SUI; no self reported incontinence (ISI =0) [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. The secondary endpoint is to compare the proportion of patients who have stress specific continence in each group. Stress specific continence requires: fulfilling criteria 1 and 2 above and 3) no self reported SUI specific symptoms. [ Time Frame: 6 months ]
  2. To compared continence, stress specific continence and patient satisfaction between groups at 12 and 24 months. [ Time Frame: 12 and 24 months ]
  3. Compare the safety of the Burch and the mid-urethral sling. [ Time Frame: 6, 12 and 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. older than 21 years of age;
  2. with symptomatic pelvic organ prolapse (POP-Q point Aa or C at ≥ -1 cm;
  3. who have opted for sacral colpopexy repair of prolapse;
  4. who have symptomatic SUI desiring surgical correction or who have occult SUI;
  5. who have urethral hypermobility;
  6. with a maximal cystometric capacity ≥ 200 cc;
  7. who are willing to return for follow-up visit; or
  8. who understand and have signed written informed consent to undergo randomization and who has given investigators permission to collect data pertaining to surgical care and follow-up.

Exclusion Criteria:

  1. with known or suspected disease that affect bladder function (i.e., multiple sclerosis, Parkinson's Disease, spinal cord injury, etc.);
  2. who are pregnant by self report or by positive pregnancy test;
  3. who desire to maintain fertility;
  4. with history of urethral diverticulum;
  5. with a history of radical pelvic surgery or pelvic radiation therapy;
  6. who are deemed medically poor candidates for abdominal surgery;
  7. Non-ambulatory (including those who ambulate with assistance; or
  8. who are actively undergoing chemotherapy or radiation treatment for malignancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00934999


Locations
Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Spectrum Health Hospitals
Saint Luke's Health System
Investigators
Layout table for investigator information
Principal Investigator: Emanuel C. Trabuco, MD, MS Mayo Clinic

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Emanuel Trabuco, Assistant Professor, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00934999     History of Changes
Other Study ID Numbers: 07-007334
94021001
First Posted: July 8, 2009    Key Record Dates
Last Update Posted: March 22, 2016
Last Verified: March 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Incontinence
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms